The World Health Organization (WHO) estimates that approximately 2 billion people worldwide have already had contact with hepatitis B virus (HBV) and 373 million have become chronic carriers. Hepatitis B is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma, leading to a large number of deaths annually. Both viral factors and the host immune response have been implicated in the pathogenesis and clinical result of HBV infection. Many Brazilian cities, including the cities of the northern region of the state of Espírito Santo are located in regions with little health infrastructure. Our study performed an epidemiological analysis of cases of Hepatitis B in São Mateus, using methodology of Geographic Information System (GIS), aiming to raise the number of disease cases, establishing preventive measures to control the disease, improving the quality of life of people affected by this pathology. The city of São Mateus had the largest number of reported cases of hepatitis B northern region of Espírito Santo. The age group with the highest number of hepatitis B notifications was 20-49 years, mostly females. The major forms of contact with HBV in these cities were dental treatment, use of injectable medications, surgical procedures and multiple sexual partners.
Background:
Helicobacter pylori is a gram-negative bacterium related to chronic gastritis, peptic
ulcer and gastric carcinoma. During its infection process, promotes excessive inflammatory response, increasing
the release of reactive species and inducing the production of pro-inflammatory mediators. Inducible Nitric
Oxide Synthase (iNOS) plays a crucial role in the gastric carcinogenesis process and a key mediator of inflammation
and host defense systems, which is expressed in macrophages induced by inflammatory stimuli. In
chronic diseases such as Helicobacter pylori infections, the overproduction of NO due to the prolonged induction
of iNOS is of major concern.
Objective:
In this sense, the search for potential iNOS inhibitors is a valuable strategy in the overall process
of Helicobacter pylori pathogeny.
Method:
In silico techniques were applied in the search of interesting compounds against Inducible Nitric
Oxide Synthase enzyme in a chemical space of natural products and derivatives from the Analyticon Discovery
databases.
Results:
The five compounds with the best iNOS inhibition profile were selected for activity and toxicity predictions.
Compound 9 (CAS 88198-99-6) displayed significant potential for iNOS inhibition, forming hydrogen
bonds with residues from the active site and an ionic interaction with heme. This compound also displayed
good bioavailability and absence of toxicity/or from its probable metabolites.
Conclusion:
The top-ranked compounds from the virtual screening workflow show promising results regarding
the iNOS inhibition profile. The results evidenced the importance of the ionic bonding during docking selection,
playing a crucial role in binding and positioning during ligand-target selection for iNOS.
Helicobacter pylori is a bacterium that reaches half of the world population and it's recognized as the main cause of chronic gastritis and peptic ulcer. In this study, we evaluated the anti-H. pylori, antioxidant and immunomodulatory activities of the methanolic (MeOH) extract of Eugenia uniflora leaves and chemical profile. Anti-H. pylori activity was evaluated by spectrophotometric broth microdilution technique by determining the HIGHLIGHTS • E. uniflora MeOH extract has anti-Helicobacter pylori activity; • E. uniflora showed antioxidant and immunomodulatory effects; • Some tannins and flavonoids identified are reported to biological activity;
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.